PD-1 immune checkpoint blockade and cytokine IL-33 have shown significant therapeutic effects in tumor immunotherapy. These therapies promote CD8 T cell activation, proliferation, and effector functions. However, there were few research about the combined therapy efficacy. In this study, we established B16-empty vector and B16-IL33 melanoma mouse models and treated with PD-1 monoclonal antibody. We reported that PD-1 blockade combined with cytokine IL-33 further inhibited tumor progression and prolonged the survival of tumor-bearing mice. Mechanistically, the combination therapy was found to further facilitate CD4 and CD8 T lymphocytes accumulation, and enhance the antitumor effects of CD4or CD8tumor-infiltrating lymphocytes by promoting type-1 immune response within the tumor microenvironment using flow cytometry and quantitative real time polymerase chain reaction. Thus, PD-1 blockade combined with IL-33 has application potential in tumor immunotherapy. Further, this study provides a new promising strategy and theoretical basis for tumor combination immunotherapy.Copyright © 2021 The Author(s). Published by Elsevier Ltd.. All rights reserved.
About The Expert
Honghong He
Liyan Shi
Dan Meng
Huijun Zhou
Jingshu Ma
Yixian Wu
Yanshi Wu
Yanzheng Gu
Wei Xie
Jing Zhang
Yibei Zhu
References
PubMed